Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear

NCT ID: NCT02362724

Last Updated: 2020-10-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the investigational contact lens to a marketed contact lens.

The study results were not used for design validation of investigational contact lens,

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this evaluation is to provide evidence supporting the claim that the performance of the Test Lens is substantially equivalent to that of the Control Lens when used in a one month (up to 30 days) recommended replacement, daily wear modality.

The study results were not used for design validation of investigational contact lens,

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ametropia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sapphire

Subjects randomized to the experimental contact lens over the study duration

Group Type EXPERIMENTAL

Sapphire

Intervention Type DEVICE

silicone hydrogel contact lens

Pearl

Subjects randomized to the active comparator contact lens over the study duration

Group Type ACTIVE_COMPARATOR

Pearl

Intervention Type DEVICE

silicone hydrogel contact lens

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sapphire

silicone hydrogel contact lens

Intervention Type DEVICE

Pearl

silicone hydrogel contact lens

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prior to being considered eligible to participate in this study, each subject MUST:

1. Be at least 18 years of age as of the date of evaluation for the study.
2. Have:

1. Read the Informed Consent
2. been given an explanation of the Informed Consent
3. indicated understanding of the Informed Consent
4. signed the Informed Consent document.
3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
4. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
5. Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
6. Be in good general health, based on his/her knowledge.
7. Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
8. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
9. To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion Criteria

* Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:

1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
2. Poor personal hygiene.
3. Any active participation in another clinical trial during this trial or within 30 days prior to this study.
4. To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
5. A member, relative or household member of the investigator or of the investigational office staff.
6. Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
7. Previous refractive surgery; or current or previous orthokeratology treatment.
8. Is aphakic or psuedophakic.
9. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
10. The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
11. The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
12. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
13. A history of papillary conjunctivitis that has interfered with contact lens wear.
14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

* Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2
* Pterygium
* Corneal scars within the visual axis
* Neovascularization or ghost vessels \> 1.0 mm in from the limbus
* Giant papillary conjunctivitis (GPC) of \> Grade 2
* Anterior uveitis or iritis
* Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Steven L Saltzman, MD, FACOG

Role: STUDY_CHAIR

Sterling IRB

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eric M White OD, Inc.

San Diego, California, United States

Site Status

Office of Mark E Nakano, O.D.

Torrance, California, United States

Site Status

Advanced Family Eye Care

Denver, North Carolina, United States

Site Status

Quinn Foster & Associates

Athens, Ohio, United States

Site Status

Primary Eyecare Group, P.C.

Brentwood, Tennessee, United States

Site Status

Premier Vision Services, LLC

Amarillo, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FC131202

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.